Genetic Technologies Limited
GENE
$2.28
-$0.01-0.44%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -8.89% | 2.57% | 19.02% | 85.04% | 292.14% |
| Total Other Revenue | -9.55% | -25.56% | -36.47% | -35.44% | -34.49% |
| Total Revenue | -9.00% | -3.47% | 4.39% | 41.21% | 111.21% |
| Cost of Revenue | -6.12% | 10.30% | 33.77% | 90.31% | 242.65% |
| Gross Profit | -10.72% | -10.95% | -9.88% | 20.81% | 71.89% |
| SG&A Expenses | -6.34% | -5.36% | -2.75% | 17.49% | 45.99% |
| Depreciation & Amortization | -4.13% | 1.21% | 8.53% | -3.46% | -13.54% |
| Other Operating Expenses | 19.86% | 35.16% | 58.37% | 19.31% | -8.17% |
| Total Operating Expenses | -1.09% | 5.57% | 15.06% | 29.28% | 48.09% |
| Operating Income | -8.40% | -16.47% | -28.06% | -18.39% | -9.02% |
| Income Before Tax | -38.02% | -44.10% | -54.19% | -30.89% | -9.00% |
| Income Tax Expenses | 94.36% | 24.56% | -359.74% | -885.34% | -- |
| Earnings from Continuing Operations | -40.72% | -45.00% | -52.83% | -29.06% | -6.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.72% | -45.00% | -52.83% | -29.06% | -6.82% |
| EBIT | -8.40% | -16.47% | -28.06% | -18.39% | -9.02% |
| EBITDA | -9.59% | -17.69% | -29.31% | -19.97% | -10.82% |
| EPS Basic | -15.25% | -24.96% | -38.97% | -21.11% | -4.51% |
| Normalized Basic EPS | 9.73% | -3.44% | -20.45% | -11.02% | -2.56% |
| EPS Diluted | -15.25% | -24.96% | -38.97% | -21.11% | -4.51% |
| Normalized Diluted EPS | 9.73% | -3.44% | -20.45% | -11.02% | -2.56% |
| Average Basic Shares Outstanding | 22.29% | 16.13% | 9.95% | 5.99% | 1.96% |
| Average Diluted Shares Outstanding | 22.29% | 16.13% | 9.95% | 5.99% | 1.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
